|
1.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2.
|
Hunter KD, Parkinson EK and Harrison PR:
Profiling early head and neck cancer. Nat Rev Cancer. 5:127–135.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Forastiere A, Koch W, Trotti A and
Sidransky D: Head and neck cancer. N Engl J Med. 345:1890–1900.
2001. View Article : Google Scholar
|
|
4.
|
Gil Z, Carlson DL, Boyle JO, et al: Lymph
node density is a significant predictor of outcome in patients with
oral cancer. Cancer. 115:5700–5710. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Mamelle G, Pampurik J, Luboinski B, Lancar
R, Lusinchi A and Bosq J: Lymph node prognostic factors in head and
neck squamous cell carcinomas. Am J Surg. 168:494–498. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Joukov V, Pajusola K, Kaipainen A, et al:
A novel vascular endothelial growth factor, VEGF-C, is a ligand for
the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
EMBO J. 15:17511996.
|
|
7.
|
Mandriota SJ, Jussila L, Jeltsch M, et al:
Vascular endothelial growth factor-C-mediated lymphangiogenesis
promotes tumour metastasis. EMBO J. 20:672–682. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Stacker SA, Caesar C, Baldwin ME, et al:
VEGF-D promotes the metastatic spread of tumor cells via the
lymphatics. Nat Med. 7:186–191. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Skobe M, Hawighorst T, Jackson DG, et al:
Induction of tumor lymphangiogenesis by VEGF-C promotes breast
cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Sleeman JP and Thiele W: Tumor metastasis
and the lymphatic vasculature. Int J Cancer. 125:2747–2756. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Makinen T, Veikkola T, Mustjoki S, et al:
Isolated lymphatic endothelial cells transduce growth, survival and
migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J.
20:4762–4773. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Roberts N, Kloos B, Cassella M, et al:
Inhibition of VEGFR-3 activation with the antagonistic antibody
more potently suppresses lymph node and distant metastases than
inactivation of VEGFR-2. Cancer Res. 66:2650–2657. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Shimizu K, Kubo H, Yamaguchi K, et al:
Suppression of VEGFR-3 signaling inhibits lymph node metastasis in
gastric cancer. Cancer Sci. 95:328–333. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Veikkola T, Jussila L, Makinen T, et al:
Signalling via vascular endothelial growth factor receptor-3 is
sufficient for lymphangiogenesis in transgenic mice. EMBO J.
20:1223–1231. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Burton JB, Priceman SJ, Sung JL, et al:
Suppression of prostate cancer nodal and systemic metastasis by
blockade of the lymphangiogenic axis. Cancer Res. 68:7828–7837.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Alitalo K and Carmeliet P: Molecular
mechanisms of lymphangiogenesis in health and disease. Cancer Cell.
1:219–227. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Dadras SS, Paul T, Bertoncini J, et al:
Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous
melanoma metastasis and survival. Am J Pathol. 162:1951–1960. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Karpanen T and Alitalo K: Lymphatic
vessels as targets of tumor therapy? J Exp Med. 194:F37–F42. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Wu KK: Inducible cyclooxygenase and nitric
oxide synthase. Adv Pharmacol. 33:179–207. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Tsujii M, Kawano S and DuBois RN:
Cyclooxygenase-2 expression in human colon cancer cells increases
metastatic potential. Proc Natl Acad Sci USA. 94:3336–3340. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Vane JR, Mitchell JA, Appleton I, et al:
Inducible isoforms of cyclooxygenase and nitric-oxide synthase in
inflammation. Proc Natl Acad Sci USA. 91:2046–2050. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Prescott SM and Fitzpatrick FA:
Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta.
1470:M69–M78. 2000.PubMed/NCBI
|
|
23.
|
Oshima M, Dinchuk JE, Kargman SL, et al:
Suppression of intestinal polyposis in Apc delta716 knockout mice
by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:803–809. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Fujita T, Matsui M, Takaku K, et al: Size-
and invasion-dependent increase in cyclooxygenase 2 levels in human
colorectal carcinomas. Cancer Res. 58:4823–4826. 1998.PubMed/NCBI
|
|
25.
|
Rozic JG, Chakraborty C and Lala PK:
Cyclooxygenase inhibitors retard murine mammary tumor progression
by reducing tumor cell migration, invasiveness and angiogenesis.
Int J Cancer. 93:497–506. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Tsujii M, Kawano S, Tsuji S, Sawaoka H,
Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced
by colon cancer cells. Cell. 93:705–716. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Williams CS, Tsujii M, Reese J, Dey SK and
DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin
Invest. 105:1589–1594. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Leahy KM, Ornberg RL, Wang Y, Zweifel BS,
Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib
reduces proliferation and induces apoptosis in angiogenic
endothelial cells in vivo. Cancer Res. 62:625–631. 2002.PubMed/NCBI
|
|
29.
|
Masferrer JL, Leahy KM, Koki AT, et al:
Antiangiogenic and antitumor activities of cyclooxygenase-2
inhibitors. Cancer Res. 60:1306–1311. 2000.PubMed/NCBI
|
|
30.
|
Takahashi K, Kanazawa, Akiyama, et al:
Establishment and characterization of a cell line (SAS) from poorly
differentiated human squamous cell carcinoma of the tongue. J Jpn
Stomatol Soc. 38:20–28. 1989.
|
|
31.
|
Shintani S, Mihara M, Nakahara Y, et al:
Lymph node metastasis of oral cancer visualized in live tissue by
green fluorescent protein expression. Oral Oncol. 38:664–669. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Iwata C, Kano MR, Komuro A, et al:
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via
reduction of lymphangiogenesis. Cancer Res. 67:10181–10189. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Hida T, Yatabe Y, Achiwa H, et al:
Increased expression of cyclooxygenase 2 occurs frequently in human
lung cancers, specifically in adenocarcinomas. Cancer Res.
58:3761–3764. 1998.PubMed/NCBI
|
|
34.
|
Ristimaki A, Honkanen N, Jankala H,
Sipponen P and Harkonen M: Expression of cyclooxygenase-2 in human
gastric carcinoma. Cancer Res. 57:1276–1280. 1997.PubMed/NCBI
|
|
35.
|
Sano H, Kawahito Y, Wilder RL, et al:
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Cancer Res. 55:3785–3789. 1995.PubMed/NCBI
|
|
36.
|
Zimmermann KC, Sarbia M, Weber AA,
Borchard F, Gabbert HE and Schror K: Cyclooxygenase-2 expression in
human esophageal carcinoma. Cancer Res. 59:198–204. 1999.PubMed/NCBI
|
|
37.
|
Choe MS, Zhang X, Shin HJ, Shin DM and
Chen ZG: Interaction between epidermal growth factor receptor- and
cyclooxygenase 2-mediated pathways and its implications for the
chemoprevention of head and neck cancer. Mol Cancer Ther.
4:1448–1455. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Mendes RA, Carvalho JF and Waal I: An
overview on the expression of cyclooxygenase-2 in tumors of the
head and neck. Oral Oncol. 45:e124–e128. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Da MX, Wu XT, Wang J, et al: Expression of
cyclooxygenase-2 and vascular endothelial growth factor-C
correlates with lymphangiogenesis and lymphatic invasion in human
gastric cancer. Arch Med Res. 39:92–99. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Su JL, Shih JY, Yen ML, et al:
Cyclooxygenase-2 induces EP1-and HER-2/Neu-dependent vascular
endothelial growth factor-C up-regulation: a novel mechanism of
lymphangiogenesis in lung adenocarcinoma. Cancer Res. 64:554–564.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Zhang XH, Huang DP, Guo GL, et al:
Coexpression of VEGF-C and COX-2 and its association with
lymphangiogenesis in human breast cancer. BMC Cancer. 8:42008.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Di JM, Zhou J, Zhou XL, et al:
Cyclooxygenase-2 expression is associated with vascular endothelial
growth factor-C and lymph node metastases in human prostate cancer.
Arch Med Res. 40:268–275. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Oka M, Iwata C, Suzuki HI, et al:
Inhibition of endogenous TGF-beta signaling enhances
lymphangiogenesis. Blood. 111:4571–4579. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Zwaans BM and Bielenberg DR: Potential
therapeutic strategies for lymphatic metastasis. Microvasc Res.
74:145–158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Burton JB, Johnson M, Sato M, et al:
Adenovirus-mediated gene expression imaging to directly detect
sentinel lymph node metastasis of prostate cancer. Nat Med.
14:882–888. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Wendt MK, Allington TM and Schiemann WP:
Mechanisms of the epithelial-mesenchymal transition by TGF-beta.
Future Oncol. 5:1145–1168. 2009. View Article : Google Scholar : PubMed/NCBI
|
